To corroborate observations in PLWH (17, 24, 25), we monitored the levels of plasma IL-10 using an ultrasensitive sandwich immunoassay in 15 SIVmac239-infected RMs that initiated a 5-drug ART regimen (raltegravir, emtricitabine, tenofovir, darunavir, ritonavir) at day 60 post-infection (d60 p.i.)(ref. 34 and Supplemental Table 1; supplemental material available online with this article; https://doi.org/10.1172/JCI155251DS1). The gene discussed is IL10; the disease is infection.